Artificial Retina Market

Company Headquarters: Illinois, US Company Working: Optobionics is the manufacturer of the Artificial Silicon Retina microchip (ASR). The chip was invented to stimulate damaged retinal cells from within the retina to allow the cells to recreate visual signals that are processed and sent to the brain. The device can be used in the treatment of retinitis pigmentosa.

Company Headquarters: France Founded: 2011 Workforce: ~30+ Company Working: Pixium Vision is a bioelectronics and brain-machine interface technology company. It connects rapid advances in visual processing, microelectronics, optoelectronics, neurobiology, and intelligent software algorithms to develop Bionic Vision Systems that utilize its competencies in machine brain interface and artificial intelligence. The company is supported by various international and multidisciplinary scientific advisory boards and partners, such as the National Health Service, Inserm, Moorfields Eye Hospital, Institut De La Vision, and The French National Center for Scientific Research (CNRS), among others.

Company Headquarters: California, US Founded: 1998 Workforce: ~123+ Company Working: Second Sight develops, manufactures, and markets prosthetic devices used as a treatment for blind individuals. Its principal office is in California, US. The company also has an office in Switzerland, which manages clinical and commercial operations in Europe, Asia, and the Middle East. It sells its products across Europe, Saudi Arabia, the US, Canada, Turkey, Iran, Taiwan, South Korea, Russia, and Singapore.

Company Headquarters: Maryland, US Founded: 1987 Workforce: ~2,500 Company Working: Novavax, Inc. is a biotechnology company that commercializes and develops vaccines to prevent a wide range of infectious diseases. It designs recombinant nanoparticle vaccine technology that produces a strong immune response against a variety of pathogens. It is partnered with leading biopharma organizations, government agencies, research institutions, and foundations, namely the Coalition for Epidemic Preparedness Innovations (US), the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (US), the Serum Institute of India Pvt. Ltd. (India), SK Bioscience (South Korea), CPL Biological (India), and Takeda Pharmaceuticals (US). It has seven research and manufacturing facilities. It has presence in regions namely North America, Europe, and the Middle East and Africa

Company Headquarters: Florida, US Founded: 1999 Workforce: ~800 Company Working: Ology Bioservices, Inc. is an integrated biopharmaceutical company that develops and manufactures biopharmaceuticals and medical devices. It specializes in cell therapy, gene therapy, viral vectors, antibodies, oncolytic viruses, biopharmaceutical manufacturing, and vaccines. It has collaboration and partnerships with recognized government agencies, namely the Department of Defense and Medical Countermeasures Advanced Development and Manufacturing, which support it in developing biodefense products. Moreover, it has decades of experience in developing, licensing, and manufacturing proteins, therapeutics, and vaccines. It develops products to offer both commercial customers and US governments. Furthermore, it is a wholly owned company of National Resilience, Inc. (US), and assisting Resilience through its services includes regulatory support from preclinical through licensure and cGMP manufacturing up to biosafety level 3 (BSL3).

Company Headquarters: New York, US Founded: 2003 Workforce: ~150 Company Working: Cleveland Biolabs, Inc. is an innovative biopharmaceutical company developing products to address immune system diseases and serious medical needs. It is specialized in offering products such as radiation injury products, immune-oncology, and orphan drugs. It has nine product candidates in its pipeline that have been developing directly through itself or its wholly owned companies, namely Incuron, LLC (US) and Panacela Labs, Inc. (US). It has a proprietary platform, namely the Advanced Immunomodulating Multi-Receptor System (AIMS) platform, which is designed to restore immune homeostasis. Moreover, it has collaboration with government agencies which supports the advanced development and procurement of new medical countermeasures including drugs, vaccines, diagnostics, and medical supplies in order to protect public health from chemical, biological, radiological, and nuclear threats.